<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757454</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB SARC-F</org_study_id>
    <nct_id>NCT04757454</nct_id>
  </id_info>
  <brief_title>Performance Indicators of the SARC-F Questionnaire in Acute Care</brief_title>
  <acronym>SARC-F-CHUB</acronym>
  <official_title>Performance Indicators of the SARC-F Questionnaire in Acute Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study applies the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs,&#xD;
      Falls (SARC-F) questionnaire in older patients hospitalized in an acute care geriatric unit&#xD;
      and aims to determine its performance indicators to screen for sarcopenia according to the&#xD;
      revised European Consensus on definition and diagnosis (EWGSOP2) within this population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher&#xD;
      risk of mobility limitation, falls, fractures, mortality, and lower quality of life. The&#xD;
      European Working Group on Sarcopenia has recently revisited one of the widely used most&#xD;
      acknowledged definitions and launched the revised European consensus on definition and&#xD;
      diagnosis (EWGSOP2) (4). Applying the EWGSOP2 is a three-tier process: first, screening by&#xD;
      the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F)&#xD;
      questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity&#xD;
      grading by low muscle function. The EWGSOP2 recommends the assessment of sarcopenia in every&#xD;
      population, both in community-dwelling and acute care older patients. However, the evidence&#xD;
      about the performance indicators of the SARC-F questionnaire to screen for sarcopenia in&#xD;
      acute patients admitted to an acute care unit is really limited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">November 11, 2020</completion_date>
  <primary_completion_date type="Actual">November 11, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the SARC-F questionnaire as screening method compared to the gold standard, which is the revised European consensus on definition and diagnosis</measure>
    <time_frame>September 2019-November 2020</time_frame>
    <description>Sensitivity, measured as a percentage (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the SARC-F questionnaire as a screening method, compared to the gold standard which is the revised European Consensus on definition and diagnosis of sarcopenia (EWGSOP2)</measure>
    <time_frame>September 2019-November 2020</time_frame>
    <description>Specificity, measured as a percentage (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall concordance agreement between the SARC-F questionnaire as a screening method and the gold standard method, which is the EWGSOP2</measure>
    <time_frame>September 2019-November 2020</time_frame>
    <description>Cohen-kappa coefficient, measured as a percentage (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health adverse outcomes based on the screening and diagnosis of sarcopenia as recommended by the EWGSOP2</measure>
    <time_frame>1-year follow-up</time_frame>
    <description>Mortality risk</description>
  </secondary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Sensitivity</condition>
  <condition>Old Age; Debility</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>5-item SARC-F questionnaire</intervention_name>
    <description>Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 65 and over hospitalized in an acute care geriatric unit due to acute medical&#xD;
        conditions, where the SARC-F questionnaire and the EWGSOP2 was available&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 65 and over&#xD;
&#xD;
          -  Hospitalized in an acute care geriatric unit due to acute health issues or acute&#xD;
             medical conditions&#xD;
&#xD;
          -  With SARC-F, hand-grip strength and dual-energy X-ray absorptiometry administered&#xD;
             during hospital admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SARC-F unavailable&#xD;
&#xD;
          -  Unwilling to collaborate in the sarcopenia assessment&#xD;
&#xD;
          -  Unwilling to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murielle Surquin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Geriatrics Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brugmann university hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Sánchez-Rodríguez D, Marco E, Dávalos-Yerovi V, López-Escobar J, Messaggi-Sartor M, Barrera C, Ronquillo-Moreno N, Vázquez-Ibar O, Calle A, Inzitari M, Piotrowicz K, Duran X, Escalada F, Muniesa JM, Duarte E. Translation and Validation of the Spanish Version of the SARC-F Questionnaire to Assess Sarcopenia in Older People. J Nutr Health Aging. 2019;23(6):518-524. doi: 10.1007/s12603-019-1204-z.</citation>
    <PMID>31233072</PMID>
  </reference>
  <reference>
    <citation>Piotrowicz K, Głuszewska A, Czesak J, Fedyk-Łukasik M, Klimek E, Sánchez-Rodríguez D, Skalska A, Gryglewska B, Grodzicki T, Gąsowski J. SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards. Aging Clin Exp Res. 2021 Jul;33(7):1821-1829. doi: 10.1007/s40520-020-01782-y. Epub 2021 Jan 28.</citation>
    <PMID>33506313</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):127-132. doi: 10.1097/MCO.0000000000000621. Review.</citation>
    <PMID>31789867</PMID>
  </reference>
  <reference>
    <citation>Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601.</citation>
    <PMID>30312372</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Murielle Surquin</investigator_full_name>
    <investigator_title>Head of the Internal Medicine and Geriatrics Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

